secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001645113-25-000010
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phase 3 PANOVA-3 trial meets primary endpoint; median OS improved to 16.2 vs 14.2 months (HR 0.82, p=0.039)
--------------------------------------------------------------------------------

- Median overall survival 16.2 months with TTFields + GnP vs 14.2 months for GnP alone; HR 0.82, p=0.039.
- One-year survival rate 68.1% vs 60.2% (p=0.029).
- Median pain-free survival 15.2 months vs 9.1 months; 6.1-month extension (HR 0.74, p=0.027).
- TTFields therapy well-tolerated with mild to moderate skin adverse events; no new safety signals.
- Company plans to file for FDA PMA approval in second half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000010/0001645113-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000010/nvcr-20250531.htm
  HTML page:      https://secwatch.observer/filing/0001645113-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer